Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Rhythm · Phase 3 · Completed · Enrollment 52

NCT03746522

EudraCT 2018-004058-11

Y axis: Change in body weight from baseline, %

0-5-1004812162024364860Pivotal Cohort, week 52, -5.21%Pivotal Cohort

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Pivotal Cohort: week 52 -5.21%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.